Schizophrenia Research
July 23, 2026
J. Daub, S. Volkmer, D. Altinok et al.
BACKGROUND Altered experiences of space and time are core features of schizophrenia spectrum disorders (SSD) and mood disorders (MOD). In this study, we investigated whether patients with SSD and MOD exhibit shared or distinct patterns of subjective spatiotemporal experience. METHODS We examined 62 ICD-11 patients (33 SSD, 29 MOD) using the Scale for Space and Time Experience in Psychosis...
Schizophrenia Research
June 16, 2026
David Olivares-Berjaga, Natàlia Rodríguez, Albert Martínez-pinteño et al.
Schizophrenia (SZ) is a neurodevelopmental disorder involving excitatory/inhibitory imbalance and apoptotic dysregulation. VDAC1, a voltage-dependent anion channel protein located in the mitochondrial outer membrane, plays a pivotal role in mitochondria-mediated apoptosis. However, its involvement in SZ remains underexplored. This study aimed to investigate VDAC1 protein levels in the...
Schizophrenia Research
June 1, 2026
L Palaniyappan, Vanteemar S Sreeraj, Ganesan Venkatasubramanian et al.
5 citations
Formal Thought Disorder (FTD) presents psychiatry's central paradox: it is one of the robust predictors of poor outcomes and polygenic risk in psychosis yet remains poorly defined and rarely measured clinically. We systematically reviewed 50 years of FTD assessment (16 rating scales, 32 factor analyses) to understand this paradox. Research to date has implicitly treated FTD as a natural kind, a...
Schizophrenia Research
March 24, 2026
Valerio Ricci, Stefania Chiappini, Giovanni Martinotti et al.
Substance-induced psychotic disorders (SIPDs) present significant clinical challenges with variable outcomes. While some patients achieve complete remission following substance cessation, others develop persistent symptoms requiring extended intervention. Understanding treatment response predictors is critical for optimizing clinical management and prognostic accuracy. Following PRISMA...
Schizophrenia Research
March 13, 2026
Michel Sabé, Paul Grof, Nathan Sackett et al.
1 citation
Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs)....
Schizophrenia Research
October 20, 2025
Elena Camon, Stefano Masier, Natália Bezerra Mota et al.
Language disorganization is a hallmark of psychosis which has traditionally been assessed through clinical interviews and standardized scales. Recent advances in Natural Language Processing (NLP) and graph theory provide innovative, objective methodologies to analyze language production in psychosis. In particular, dream reports, as a unique form of narrative, offer a valuable lens through...
Schizophrenia Research
July 1, 2025
Antonia Meinhart, Annika Schmueser, Steffen Moritz et al.
4 citations
Mindfulness- and acceptance-based interventions (MBIs/ABIs) for persons with schizophrenia spectrum disorders (SSD) aim to cultivate purposeful attention, mind-body awareness, and targeted action-taking. This systematic meta-review assessed the current body of evidence regarding the effects of MBIs/ABIs for SSD symptoms. The study was registered with PROSPERO (CRD42024535284) on June 3, 2024....
Schizophrenia Research
June 2, 2025
Maria Chiara Piani, Martin Jandl, Thomas Koenig et al.
3 citations
Self-disorders (SDs), central features of schizophrenia spectrum disorders, primarily affect the pre-reflective sense of self, the fundamental experience of existing as a conscious subject. This disruption also impacts reflective self-consciousness. This study aims to further explore the neural correlates of self-disorders in individuals with schizophrenia spectrum disorders by using a...
Schizophrenia Research
April 1, 2025
Sofia de Almeida Queiroz, Linério Ribeiro de Novais Junior, Anita Beatriz Pacheco de Carvalho et al.
2 citations
Schizophrenia (SCZ) has limited treatment options, often with significant side effects. Cannabidiol (CBD), a non-euphoric phytocannabinoid, has shown potential as a novel therapeutic option in SCZ due to antipsychotic-like, anti-inflammatory, and antioxidant properties. We compared the therapeutic effects of CBD and risperidone (RISP) in a rat model of SCZ induced by sub-chronic ketamine (KET),...
Schizophrenia Research
October 1, 2024
Michele Poletti, Andrea Raballo
10 citations
The concept of basic Self-disorders (SD) captures the experiential aspects associated with vulnerability to schizophrenia spectrum disorders (SSD). SD emerge prior to, and constitute the underlying structure for, the emergence of major diagnostic symptoms, including positive psychotic ones. SD are also detectable in populations with familial risk for SSD. This paper proposes a two-stage...
Schizophrenia Research
September 1, 2024
Ana Teresa Caliman-Fontes, Flávia Vieira, Gustavo C. Leal et al.
7 citations
Catatonia, documented since the 19th century, remains a significant challenge in terms of recognition and treatment. Over the last two decades, ketamine has brought new perspectives to psychiatry, sparking widespread interest. Concurrently, catatonia has attracted heightened scientific attention. Preliminary evidence suggests the therapeutic potential of ketamine for catatonia. We...
Schizophrenia Research
August 1, 2024
Josef Parnas, Karl Erik Sandsten
17 citations
Schizophrenia continues its resistance to the pathogenetic understanding. We believe that one of the reasons is an oblivion of schizophrenia's characteristic Gestalt expressive of its psychopathological structure. In this article we argue for a crucial role of disorders of selfhood in the constitution of this Gestalt. First, we present a phenomenological account of the self. This is followed by...
Schizophrenia Research
July 1, 2024
Vittorio Gallese, Martina Ardizzi, Francesca Ferroni
18 citations
Despite the historically consolidated psychopathological perspective, on the one hand, contemporary organicistic psychiatry often highlights abnormalities in neurotransmitter systems like dysregulation of dopamine transmission, neural circuitry, and genetic factors as key contributors to schizophrenia. Neuroscience, on the other, has so far almost entirely neglected the first-person...
Schizophrenia Research
March 1, 2024
Josef Parnas, Janne-Elin Yttri, Annick Urfer-Parnas
28 citations
This study presents phenomenological features of auditory verbal hallucinations (AVH) in schizophrenia and associated anomalies of experience. The purpose is to compare the lived experience of AVH to the official definition of hallucinations as a perception without object. Furthermore, we wish to explore the clinical and research implication of the phenomenological approach to AVH. Our...
Schizophrenia Research
February 1, 2024
Andreas Rosén Rasmussen
8 citations
In 20th century psychiatry, various disturbances of imagination were discussed in the context of schizophrenia. Today, these notions have almost completely vanished from mainstream psychopathology. However, recent work has suggested that specific phenomena within this area have a relevance for differential diagnosis and early detection of psychosis. This paper first provides an overview of 20th...
Schizophrenia Research
February 1, 2024
Michel Sabé, Raoul Kohler, Natacha Perez et al.
Mindfulness-based interventions (MBIs) have emerged as secular practices, including elements of mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT). While MBIs have been widely adopted for physical and mental illness, only a few available programs are explicitly adapted for psychosis. However, previous reviews have reported the vital heterogeneity regarding...
Schizophrenia Research
2024
Georg Northoff, Dusan Hirjak
Catatonia is featured by complex symptoms combining motor, affective and behavioral phenomena as well as by its syndrome character with trans-diagnostic occurrence. It paradigmatically shows the limits of current forms of psychopathology like affective and cognitive approaches with respect to both clinical symptoms and brain mechanisms. We therefore suggest Spatiotemporal Psychopathology (STPP)...
Schizophrenia Research
September 1, 2023
Angelica M Silva, Roberto Limongi, Michael Mackinley et al.
49 citations
In the clinical linguistics of schizophrenia, syntactic complexity has received much attention. In this study, we address whether syntactic complexity deteriorates within the six months following the first episode of psychosis in those who develop a diagnosis of schizophrenia. We collected data from a cohort of twenty-six first-episode psychosis and 12 healthy control subjects using the Thought...
Schizophrenia Research
August 25, 2022
Olga Santesteban-Echarri, Lu Liu, Madeline Miller et al.
Cannabis use is more prevalent among youth at clinical high-risk (CHR) for psychosis than healthy controls (HC). There is mixed evidence as to whether cannabis use is associated with increased severity of attenuated psychotic symptoms (APS) or whether current cannabis use is associated with the transition to psychosis. This study aims to assess cannabis use differences between CHR youth and HC...
Schizophrenia Research
May 1, 2022
Andreas Rosén Rasmussen, Josef Parnas
Obsessive-compulsive symptoms are frequent in schizophrenia-spectrum disorders and often cause differential diagnostic challenges, especially in first-contact patients. Drawing upon phenomenology of cognition, we critically review classic and contemporary psychopathological notions of obsessive-compulsive phenomena and discuss their relevance for differential diagnosis between...
Schizophrenia Research
September 9, 2021
T. J. Tao, C. Hui, Bertha S. T. Lam et al.
Mindfulness meditation (MM) and its alignment with the mind-body perspective of health in Chinese cultures indicate its potential to benefit Chinese patients with psychosis. This is the first systematic review and meta-analysis to address the following questions: (1) Does MM improve clinical, well-being, and third-wave outcomes (i.e., mindfulness, acceptance, and compassion levels) among...
Schizophrenia Research
July 1, 2020
Timo Hennig, Björn Schlier, Tania M Lincoln
Experimental research has shown that poor sleep triggers psychotic experiences, even in healthy participants. This warrants an in-depth investigation of this mechanism in a naturalistic environment, an exploration of which particular aspects of poor sleep trigger psychotic symptoms, and a test for reverse effects of symptoms on sleep. For this purpose, we conducted a 14-day ambulatory...
Schizophrenia Research
April 6, 2020
Colm O’Tuathaigh, Christopher Dawes, Andrea Bickerdike et al.
13 citations
Cannabis can induce acute psychotic symptoms in healthy individuals and exacerbate pre-existing psychotic symptoms in patients with schizophrenia. Inappropriate salience allocation is hypothesised to be central to the association between dopamine dysregulation and psychotic symptoms. This study examined whether cannabis use is associated with self-reported salience dysfunction and schizotypal...
Schizophrenia Research
April 1, 2020
Karl Erik Sandsten, Julie Nordgaard, Troels Wesenberg Kjaer et al.
45 citations
Self-alienation is a common characterization of various disturbing experiences in patients with schizophrenia. A vivid example comes from patient reports of not recognizing themselves when inspecting their specular image in the mirror. By applying the multisensory paradigm of the Enfacement Illusion, this study empirically addresses the specular Self-Other discrimination in patients with...
Schizophrenia Research
October 1, 2019
Michel Sabé, Othman Sentissi, Stefan Kaiser
Meditation-based mind-body therapies (yoga, tai-chi, qi-gong, mindfulness) have been suggested to have a potential therapeutic effect on negative symptoms. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) examining effectiveness of yoga, tai-chi, qi-gong and mindfulness on negative symptoms of schizophrenia, using different databases and trial...